Use of Prescription Antiemetics Among US Commercially Insured Pregnant Patients, 2005-2019

Thuy N Thai; Joshua Brown; Stephan Schmidt; Judith Maro; Sonja A Rasmussen; Almut G Winterstein

doi:10.1001/jamanetworkopen.2024.40414

Use of Prescription Antiemetics Among US Commercially Insured Pregnant Patients, 2005-2019

JAMA Netw Open. 2024 Oct 1;7(10):e2440414. doi: 10.1001/jamanetworkopen.2024.40414.

Authors

Thuy N Thai^{1

2

3}, Joshua Brown^{2

3}, Stephan Schmidt⁴, Judith Maro¹, Sonja A Rasmussen⁵, Almut G Winterstein^{2

3

6}

Affiliations

¹ Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.
² Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.
³ Center for Drug Evaluation and Safety (CoDES), University of Florida, Gainesville.
⁴ Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville.
⁵ Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁶ Department of Epidemiology, College of Medicine and College of Public Health and Health Professions, University of Florida, Gainesville.

No abstract available

Plain language summary

This cohort study investigates prescription antiemetic treatment patterns considering monotherapy, switching, and combination therapy during the first trimester of pregnancy and evaluates factors associated with ondansetron use.